$116 Million is the total value of DAFNA Capital Management LLC's 46 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 52.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVDQ | Sell | NOVADAQ TECHNOLOGIES INC | $5,872,000 | +25.4% | 263,541 | -7.2% | 5.05% | +4.7% |
| STXS | Sell | STEREOTAXIS INC | $5,871,000 | -6.7% | 1,381,460 | -20.5% | 5.05% | -22.1% |
| PODD | Sell | INSULET CORP | $5,189,000 | +15.1% | 109,418 | -9.9% | 4.46% | -3.9% |
| Sell | INSULET CORPnote 3.750% 6/1 | $4,752,000 | +8.7% | 2,625,000 | -12.5% | 4.08% | -9.2% | |
| THLD | Sell | THRESHOLD PHARMACEUTICAL INC | $1,288,000 | -1.7% | 270,500 | -3.6% | 1.11% | -17.9% |
| SPNC | Sell | SPECTRANETICS CORP | $1,278,000 | -2.4% | 42,162 | -19.5% | 1.10% | -18.5% |
| CRDC | Sell | CARDICA INC | $1,055,000 | +1.7% | 1,053,704 | -0.9% | 0.91% | -15.0% |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $660,000 | +0.8% | 2,000 | -79.2% | 0.57% | -15.9% |
| APPY | Sell | VENAXIS INC | $192,000 | -84.8% | 73,000 | -87.6% | 0.16% | -87.3% |
| CBMXW | Exit | COMBIMATRIX CORP*w exp 05/01/201 | $0 | – | -2,325 | -100.0% | -0.00% | – |
| PTN | Exit | PALATIN TECHNOLOGIES INC | $0 | – | -344,690 | -100.0% | -0.26% | – |
| SYN | Exit | SYNTHETIC BIOLOGICS INC | $0 | – | -184,900 | -100.0% | -0.29% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -75,000 | -100.0% | -0.30% | – |
| BAXSQ | Exit | BAXANO SURGICAL INC | $0 | – | -336,351 | -100.0% | -0.35% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -290,000 | -100.0% | -0.58% | – |
| DYAX | Exit | DYAX CORP | $0 | – | -75,500 | -100.0% | -0.59% | – |
| CNAT | Exit | CONATUS PHARMACEUTICALS INC | $0 | – | -135,666 | -100.0% | -0.90% | – |
| OGXI | Exit | ONCOGENEX PHARMACEUTICAL INC | $0 | – | -111,245 | -100.0% | -0.96% | – |
| GIVN | Exit | GIVEN IMAGING | $0 | – | -156,320 | -100.0% | -4.84% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.